Terapie pacientky s myelodysplastickým syndromem s přetížením železem perorálním chelátorem deferasiroxem
| Číslo: | 3 / 2010 (Obsah) |
| Rubrika: | Kazuistiky / Klinická praxe |
| Obor: | Hematologie |
| Autoři: | MUDr. Anna Jonášová |
| Autoři - působiště: | I. interní klinika 1. LF UK a VFN, Praha |
| Citace: | 1 Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with MDS. Haematologica 2006;91:1588–90. 2 Armand P, Kim HT, Aleza EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586–8. 3 Leitch HA, Wong DHC, Leger CS, et al. Improved leukemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. Blood 2007;110:abstract 1469. 4 Rose C, Brechignac S, Dreyfus F, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused mds patients. A prospective analysis by the GFM. Blood 2007;110:abstract 249. 5 List A, Baer MR, Steensma D, et al. Iron chelation therapy with deferasirox (ICL670) reduces serum ferritin and labile plasma iron (LIP) in patients with myelodysplastic syndromes (MDS). Haematologica 2008;93(Suppl 1):abstract 0228. 6 Gattermann N, Schmidt M, Rose CH, et al. Efficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood 2008;112:abstract 633. 7 List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade®) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008;112: abstract 634. 8 Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594–603. |
Souhrn
Myelodysplastický syndrom (MDS) je heterogenní skupina onemocnění, pro něž je charakteristická diskrepance mezi bohatou krvetvorbou a periferní pancytopenií jako následek neefektivní hematopoezy s klinickými projevy anemie, infekce a krvácením. Možná je transformace do akutní leukemie.
Literatura
- 1
- Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with MDS. Haematologica 2006;91:1588–90. 2 Armand P, Kim HT, Aleza EP, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007;109:4586–8. 3 Leitch HA, Wong DHC, Leger CS, et al. Improved leukemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis. Blood 2007;110:abstract 1469. 4 Rose C, Brechignac S, Dreyfus F, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused mds patients. A prospective analysis by the GFM. Blood 2007;110:abstract 249. 5 List A, Baer MR, Steensma D, et al. Iron chelation therapy with deferasirox (ICL670) reduces serum ferritin and labile plasma iron (LIP) in patients with myelodysplastic syndromes (MDS). Haematologica 2008;93(Suppl 1):abstract 0228. 6 Gattermann N, Schmidt M, Rose CH, et al. Efficacy and safety of deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial. Blood 2008;112:abstract 633. 7 List AF, Baer MR, Steensma D, et al. Iron chelation with deferasirox (Exjade®) improves iron burden in patients with myelodysplastic syndromes (MDS). Blood 2008;112: abstract 634. 8 Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005;23:7594–603.
Celý článek je dostupný jen pro předplatitele časopisu
Přihlášení
Předplatné
Aktuální číslo
Nové trendy ve farmakoterapii
Profily léčiv
Farmakoterapeutické postupy
- Imunomodulační vlastnosti bevacizumabu a jejich přínos v kombinaci s atezolizumabem – studie IMpower150
- Kabozantinib v léčbě hepatocelulárního karcinomu
- Kabozantinib v léčbě RCC
- Malobuněčný bronchogenní karcinom: vyhlídky do budoucnosti
- Nivolumab v léčbě klasického Hodgkinova lymfomu
- Pembrolizumab v 1. linii léčby NSCLC
- Postavení adjuvantní léčby v terapii melanomu
- Postavení kombinace amlodipinu s inhibitory RAAS v léčbě hypertenze
- Současné možnosti léčby spondyloartritid
- Trazodon a jeho využití v léčbě depresivní poruchy